Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis.
What: Shares of MAKO Surgical
So what: RIO system sales came in at just nine systems, following up its disappointing first quarter, which saw only six systems sold. There were a total of 2,590 MAKOplasty procedures performed during the quarter, which was a 66% increase over last year. The company also sold nine total hip arthroplasty applications.
Now what: MAKO has had a rough year so far, even when acknowledging the back-end-loaded nature of its business with most purchases usually taking place during the latter half of each year. CEO Maurice Ferre expressed optimism in long-term growth, but said the company's near-term focus will be improving execution. For the second consecutive quarter, MAKO has now slashed full-year RIO system sales guidance and now expects to sell only 42 to 48 systems this year.
Interested in more info on MAKO Surgical? Add it to your watchlist by clicking here.